<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851745</url>
  </required_header>
  <id_info>
    <org_study_id>G113</org_study_id>
    <nct_id>NCT02851745</nct_id>
  </id_info>
  <brief_title>Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry</brief_title>
  <acronym>DYDA2</acronym>
  <official_title>Effects of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart Care Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione dell’Associazione Medici Diabetologi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heart Care Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the effect of linagliptin 5 mg daily versus
      the corresponding placebo on the LV systolic function (measured by midwall shortening
      analysis) in patients with T2DM and a documented baseline concentric LV geometry and LV
      systolic dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre, randomized, double blind, parallel group comparison of an DPP-4 inhibitor,
      linagliptin 5 mg od, versus placebo (1:1) in patients with T2DM and a documented baseline
      concentric LV geometry and LV systolic dysfunction.

      The management of glycemia will be left to the Investigator's judgment informed by clinical
      guidelines. The Investigator will therefore be allowed to undertake appropriate action, i.e.:

        -  Adjust the background antidiabetic treatment.

        -  Prescribe an additional antidiabetic medication according to its labeling (with the
           exclusion of other DPP-4 inhibitor or GLP-1 receptor agonist).

      The enrollment period will last 12 months. The patients will be followed up for 48 weeks from
      randomization.

      After the randomization the patients will have a control visit after 2 weeks (Visit 3) and at
      3 months from randomization (Visit 4, week 12). At Visit 4 blood samples will be collected.

      Afterwards the patients will have one control visit at 24 weeks from randomization (Visit 5)
      and a final visit at 48 weeks from randomization (Visit 6) with echocardiogram and ECG
      performed and blood samples collected.

      Patients still on study treatment at the time of final visit (Visit 6) will have a post
      treatment safety follow up (clinical visit or phone contact) 30 days after the study
      treatment discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in LV systolic function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Statistically significant change (equivalent to an increase of 10%) from baseline to 48 weeks of LV systolic function measured by analysis of the MFS (centralized reading).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in diastolic LV function</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes from baseline to 48 weeks of diastolic LV function (centralized reading) classified, in the two moments of evaluation, in 4 stages: normal, mild dysfunction, moderate and severe dysfunction. The efficacy of treatment will be evaluated both in terms of significant reduction of the parameter E / E 'expressed as a continuous variable and as entity improvement of dysfunction analyzed by degrees, as described above.
Changes from baseline to 48 weeks of longitudinal LV systolic function (centralized reading) measured by tissue Doppler (peak systolic velocity of the wave S 'mitral ring); percentage of patients showing an improvement of S '&gt; 25% from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Left Ventricular Systolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin 5 mg daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 5 mg daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <arm_group_label>Linagliptin</arm_group_label>
    <other_name>Trajenta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged equal to or more than 40 years at screening.

          -  Patients with history of T2DM lasting at least six month prior to the screening visit.

          -  HbA1c ≤ 8.0% (≤ 64 mmol/mol) at screening.

          -  Evidence of sinus rhythm at screening ECG evaluation

          -  No clinical signs/symptoms of a cardiac disease and no evidence of coronary artery
             disease on the basis of clinical, electrocardiographic and echocardiographic
             evaluation at screening.

          -  Evidence at baseline echocardiographic examination of concentric left ventricular
             geometry, defined as relative wall thickness ≥ 0.42. Relative wall thickness was
             calculated as the end-diastolic ratio 2* posterior wall thickness/LV diameter.

          -  Evidence at baseline echocardiographic examination of LV systolic dysfunction defined
             as Midwall shortening (MFS) ≤15%

          -  Obtained informed consent

        Exclusion Criteria:

          -  Patients with a confirmed indication for an incretin treatment

          -  Uncontrolled diabetes: HbA1c &gt;8.0% (&gt; 64 mmol/mol) or Fasting Plasma Glucose &gt; 300
             mg/dL measured at screening visit.

          -  Glitazones within the last three months

          -  Permanent atrial fibrillation

          -  Uncontrolled hypertension (defined as systolic blood pressure&gt;160 and/or diastolic
             blood pressure &gt;90)

          -  Unstable dosage and changes in type of antihypertensive, lipid lowering and
             antidiabetic drugs within 4 weeks before the screening visit.

          -  Severe chronic renal dysfunction (defined as estimated glomerular filtration rate &lt; 30
             ml/min/1.73 m2).

          -  Previous or current documented history of untreated (by using CPAP) obstructive sleep
             apnea syndrome

          -  Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis.

          -  Previous or current documented history of malignant disease

          -  Pregnancy and breast feeding

          -  Documented alcohol and drug abuse

          -  Anticipated poor compliance

          -  Current participation in a clinical trial with other investigational products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo B. Giorda, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale Maggiore - Diabetologia Malattie Metaboliche - Chieri</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni Xxiii</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. Garibaldi-Nesima</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo Della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Villa Scassi</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iclas-Istituto Clinico Ligure Alta Spec.</name>
      <address>
        <city>Rapallo</city>
        <state>GE</state>
        <zip>16035</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe Da Copertino</name>
      <address>
        <city>Copertino</city>
        <state>LE</state>
        <zip>73043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G. Martino</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Policlinico Multimedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>MI</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>Piemonte</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sandro Pertini</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Chieri</city>
        <state>TO</state>
        <zip>10023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mauriziano</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aas 1 Triestina</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aorn Osp. Dei Colli- Po Vincenzo Monaldi</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seconda Universita' Di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Villa Bianca</name>
      <address>
        <city>Trento</city>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

